The U.S. Food and Drug Administration (FDA) has declined to approve Eli Lilly and partner Innovent Biologics Inc's lung cancer drug that had been studied only in China, Lilly said on Thursday.
The decision comes after a panel of advisers to the regulator in February recommended that the companies should be required to conduct a trial of the drug, sintilimab, that is applicable to the U.S. population.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments